Literature DB >> 34056602

CovidNeuroOnc: A UK multicenter, prospective cohort study of the impact of the COVID-19 pandemic on the neuro-oncology service.

Daniel M Fountain1,2, Rory J Piper3, Michael T C Poon4, Georgios Solomou5, Paul M Brennan6, Yasir A Chowdhury7, Francesca Colombo1,2, Tarek Elmoslemany8,9, Frederick G Ewbank10, Paul L Grundy10, Md T Hasan1,2, Molly Hilling11, Peter J Hutchinson12, Konstantina Karabatsou1,2, Angelos G Kolias12, Nathan J McSorley13, Christopher P Millward8, Isaac Phang14, Puneet Plaha3, Stephen J Price12, Ola Rominiyi15, William Sage16, Syed Shumon17, Ines L Silva11, Stuart J Smith16, Surash Surash17, Simon Thomson18, Jun Y Lau3, Colin Watts7,19, Michael D Jenkinson8,9.   

Abstract

BACKGROUND: The COVID-19 pandemic has profoundly affected cancer services. Our objective was to determine the effect of the COVID-19 pandemic on decision making and the resulting outcomes for patients with newly diagnosed or recurrent intracranial tumors.
METHODS: We performed a multicenter prospective study of all adult patients discussed in weekly neuro-oncology and skull base multidisciplinary team meetings who had a newly diagnosed or recurrent intracranial (excluding pituitary) tumor between 01 April and 31 May 2020. All patients had at least 30-day follow-up data. Descriptive statistical reporting was used.
RESULTS: There were 1357 referrals for newly diagnosed or recurrent intracranial tumors across 15 neuro-oncology centers. Of centers with all intracranial tumors, a change in initial management was reported in 8.6% of cases (n = 104/1210). Decisions to change the management plan reduced over time from a peak of 19% referrals at the start of the study to 0% by the end of the study period. Changes in management were reported in 16% (n = 75/466) of cases previously recommended for surgery and 28% of cases previously recommended for chemotherapy (n = 20/72). The reported SARS-CoV-2 infection rate was similar in surgical and non-surgical patients (2.6% vs. 2.4%, P > .9).
CONCLUSIONS: Disruption to neuro-oncology services in the UK caused by the COVID-19 pandemic was most marked in the first month, affecting all diagnoses. Patients considered for chemotherapy were most affected. In those recommended surgical treatment this was successfully completed. Longer-term outcome data will evaluate oncological treatments received by these patients and overall survival.
© The Author(s) 2021. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; brain tumor; intracranial tumor; neuro-oncology

Year:  2021        PMID: 34056602      PMCID: PMC7928638          DOI: 10.1093/noajnl/vdab014

Source DB:  PubMed          Journal:  Neurooncol Adv        ISSN: 2632-2498


  12 in total

1.  Glioblastoma in England: 2007-2011.

Authors:  Andrew Brodbelt; David Greenberg; Tim Winters; Matt Williams; Sally Vernon; V Peter Collins
Journal:  Eur J Cancer       Date:  2015-02-03       Impact factor: 9.162

2.  Letter: The Impact of the Coronavirus (COVID-19) Pandemic on Neurosurgeons Worldwide.

Authors:  Nasser M F El-Ghandour; Eman H Elsebaie; Amany A Salem; Abdullah F Alkhamees; Mohamed A Zaazoue; Mohammed A Fouda; Rasha G Elbadry; Mohamed Aly; Hebatalla Bakr; Mohamed A Labib; Matthew K Tobin; Cristian Gragnaniello; Pablo Gonzalez-Lopez; Abdalla Shamisa; Balraj S Jhawar; Mohamed A R Soliman
Journal:  Neurosurgery       Date:  2020-08-01       Impact factor: 4.654

3.  Neuro-oncology Management During the COVID-19 Pandemic With a Focus on WHO Grade III and IV Gliomas.

Authors:  Denise Bernhardt; Wolfgang Wick; Stephanie E Weiss; Arjun Sahgal; Simon S Lo; John H Suh; Eric L Chang; Matthew Foote; James Perry; Bernhard Meyer; Peter Vajkoczy; Patrick Y Wen; Christoph Straube; Steffi Pigorsch; Jan J Wilkens; Stephanie E Combs
Journal:  Neuro Oncol       Date:  2020-05-05       Impact factor: 12.300

4.  Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study.

Authors: 
Journal:  Lancet       Date:  2020-05-29       Impact factor: 79.321

5.  COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study.

Authors:  Lennard Yw Lee; Jean-Baptiste Cazier; Vasileios Angelis; Roland Arnold; Vartika Bisht; Naomi A Campton; Julia Chackathayil; Vinton Wt Cheng; Helen M Curley; Matthew W Fittall; Luke Freeman-Mills; Spyridon Gennatas; Anshita Goel; Simon Hartley; Daniel J Hughes; David Kerr; Alvin Jx Lee; Rebecca J Lee; Sophie E McGrath; Christopher P Middleton; Nirupa Murugaesu; Thomas Newsom-Davis; Alicia Fc Okines; Anna C Olsson-Brown; Claire Palles; Yi Pan; Ruth Pettengell; Thomas Powles; Emily A Protheroe; Karin Purshouse; Archana Sharma-Oates; Shivan Sivakumar; Ashley J Smith; Thomas Starkey; Chris D Turnbull; Csilla Várnai; Nadia Yousaf; Rachel Kerr; Gary Middleton
Journal:  Lancet       Date:  2020-05-28       Impact factor: 79.321

6.  The impact of COVID-19 on neurosurgeons and the strategy for triaging non-emergent operations: a global neurosurgery study.

Authors:  Walter C Jean; Natasha T Ironside; Kenneth D Sack; Daniel R Felbaum; Hasan R Syed
Journal:  Acta Neurochir (Wien)       Date:  2020-04-21       Impact factor: 2.216

7.  Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands.

Authors:  Avinash G Dinmohamed; Otto Visser; Rob H A Verhoeven; Marieke W J Louwman; Francien H van Nederveen; Stefan M Willems; Matthias A W Merkx; Valery E P P Lemmens; Iris D Nagtegaal; Sabine Siesling
Journal:  Lancet Oncol       Date:  2020-04-30       Impact factor: 41.316

8.  Collateral damage: the impact on outcomes from cancer surgery of the COVID-19 pandemic.

Authors:  A Sud; M E Jones; J Broggio; C Loveday; B Torr; A Garrett; D L Nicol; S Jhanji; S A Boyce; F Gronthoud; P Ward; J M Handy; N Yousaf; J Larkin; Y-E Suh; S Scott; P D P Pharoah; C Swanton; C Abbosh; M Williams; G Lyratzopoulos; R Houlston; C Turnbull
Journal:  Ann Oncol       Date:  2020-05-19       Impact factor: 32.976

9.  Elective surgery cancellations due to the COVID-19 pandemic: global predictive modelling to inform surgical recovery plans.

Authors: 
Journal:  Br J Surg       Date:  2020-06-13       Impact factor: 6.939

10.  Impact of COVID-19 pandemic on surgical neuro-oncology multi-disciplinary team decision making: a national survey (COVID-CNSMDT Study).

Authors:  Stephen John Price; Alexis Joannides; Puneet Plaha; Fardad Taghizadeh Afshari; Erminia Albanese; Neil U Barua; Huan Wee Chan; Giles Critchley; Thomas Flannery; Daniel M Fountain; Ryan K Mathew; Rory J Piper; Michael Tc Poon; Chittoor Rajaraman; Ola Rominiyi; Stuart Smith; Georgios Solomou; Anna Solth; Surash Surash; Victoria Wykes; Colin Watts; Helen Bulbeck; Peter Hutchinson; Michael D Jenkinson
Journal:  BMJ Open       Date:  2020-08-16       Impact factor: 2.692

View more
  2 in total

Review 1.  Practice Patterns in Surgical Neuro-Oncology Among Low- and Middle-Income Countries During the Coronavirus Disease 2019 Pandemic: A Scoping Review and Situational Report from the Philippines.

Authors:  Juan Silvestre G Pascual; Katrina Hannah D Ignacio; Michelle Regina L Castillo; Kathleen Joy O Khu
Journal:  World Neurosurg       Date:  2021-12-11       Impact factor: 2.104

Review 2.  How has the COVID-19 pandemic impacted clinical care and research in Neuro-Oncology?

Authors:  Angus Airth; James R Whittle; James Dimou
Journal:  J Clin Neurosci       Date:  2022-09-08       Impact factor: 2.116

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.